Why Farbe Firma is the Top Manufacturer of Midazolam Injection
- Maulik Sudani
- 3 hours ago
- 5 min read
Last Updated: May 13, 2026
TL;DR: Midazolam Injection is a short-acting benzodiazepine used worldwide for procedural sedation, anesthesia induction, status epilepticus, and ICU sedation — and Farbe Firma manufactures it under WHO-GMP certified ISO Class 5 conditions in Gujarat, India, with controlled-substance documentation support and exports to 30+ countries.
Key Takeaways
Midazolam Injection is a water-soluble benzodiazepine of choice for procedural sedation, anesthesia induction, status epilepticus, and ICU sedation.
Farbe Firma manufactures Midazolam Injection under WHO-GMP, ISO 9001:2015, and ISO Class 5 aseptic processing — with sterility, endotoxin, assay, and pH release testing on every batch.
Standard strengths include 1 mg/mL and 5 mg/mL in 1 mL, 3 mL, and 5 mL clear glass ampoules and vials, with light-resistant secondary packaging.
Buyers receive CTD/ACTD dossiers, controlled-substance import-export support, BMR/BPR, and registration assistance across Latin America, CIS, Africa, MENA, and Southeast Asia.
Introduction
Midazolam Injection has become the benzodiazepine of choice across emergency medicine, anesthesia, and critical care due to its rapid onset, short duration, predictable pharmacokinetics, and water-soluble formulation that eliminates the propylene glycol toxicity seen with older benzodiazepines. Whether for procedural sedation in endoscopy and cardiology suites, induction of general anesthesia, control of status epilepticus, or long-term sedation of mechanically ventilated ICU patients, midazolam is one of the most clinically versatile sedative-hypnotics ever introduced.
Because midazolam is a Schedule IV controlled substance in most jurisdictions, sourcing it from a manufacturer who understands both pharmaceutical quality and the regulatory paperwork around controlled-substance import-export is essential. Farbe Firma Pvt Ltd, a WHO-GMP certified sterile injectable manufacturer in Gujarat, India, produces Midazolam Injection under fully validated aseptic conditions and supports buyers across 30+ countries with the dossiers, narcotic licenses, and export permits required for compliant distribution.
Understanding Midazolam Injection
Midazolam is an imidazobenzodiazepine that enhances GABA-A receptor activity in the central nervous system, producing dose-dependent anxiolysis, sedation, anterograde amnesia, anticonvulsant action, and skeletal muscle relaxation. Unlike diazepam, midazolam is water-soluble at acidic pH and lipid-soluble at physiological pH — a property that enables aqueous IV/IM formulation while allowing rapid blood-brain barrier penetration after injection. Onset of action is 1–5 minutes IV, with elimination half-life of 1.5–3 hours, making it ideal for short procedures and titratable sedation.
Clinical applications include preoperative sedation, induction and maintenance of general anesthesia, procedural sedation for endoscopy and minor surgery, control of acute seizures and status epilepticus, ICU sedation in ventilated patients, and palliative care for terminal restlessness. Pediatric, adult, and geriatric dosing differ markedly, and the WHO Model List of Essential Medicines includes midazolam injection as a core anticonvulsant and anesthetic. Quality and consistency of every ampoule and vial directly affect titration accuracy at the bedside.
Critical Quality Attributes for Midazolam Injection
Midazolam Injection is formulated as midazolam hydrochloride or maleate at acidic pH (typically 3.0–3.6), using hydrochloric acid for pH adjustment and water for injection as solvent. The acidic pH preserves the water-soluble form and prevents precipitation. Manufacturers must validate pH control across the entire batch, demonstrate uniform assay (HPLC) within tight USP/Ph. Eur. limits, ensure absence of related substances above ICH Q3B thresholds, and confirm sterility and bacterial endotoxin compliance.
Because midazolam is a controlled substance, manufacturers also maintain DEA-equivalent or Narcotics Control Bureau (India) inventory records, batch-to-batch chain-of-custody, and reconciliation of every ampoule from API receipt to finished-goods dispatch. Aseptic processing under ISO Class 5 conditions is the default route — terminal sterilization is generally avoided to prevent thermal degradation of the API. Light-resistant secondary cartons and 2–8 °C cold-chain handling during certain transit conditions further protect the product.
Looking for a trusted manufacturer? Submit a Quick Inquiry
Farbe Firma's Midazolam Injection Manufacturing Capability
Farbe Firma manufactures Midazolam Injection in our purpose-built sterile facility in Ankleshwar, Gujarat. Our SVP line uses fully validated aseptic processing under ISO Class 5 laminar airflow with continuous environmental monitoring, restricted-access barrier systems where required, and automated visual inspection. Standard strengths include 1 mg/mL and 5 mg/mL in 1 mL, 3 mL, and 5 mL clear glass ampoules and vials. Every batch is released only after sterility, bacterial endotoxin, HPLC assay, related substances, pH, particulate matter, and visual inspection compliance.
Our controlled-substance team handles the regulatory paperwork that buyers in tightly controlled markets require — import permits, export authorizations, narcotic statements, and chain-of-custody documentation. We coordinate with the Narcotics Control Bureau in India and with the buyer's national narcotics authority to ensure that every shipment moves with the proper authorizations. For long-term partners, we maintain dedicated production slots and stock buffers, since controlled-substance lead times can extend if permits are not pre-aligned.
Why Farbe Firma
Farbe Firma Pvt Ltd is a WHO-GMP certified pharmaceutical injectable manufacturer headquartered in Gujarat, India. Our facility runs ISO Class 5 cleanrooms for aseptic processing, validated lyophilization lines, and high-speed ampoule and vial filling under continuous environmental monitoring. We manufacture 100+ injectables across anesthesia, sedation, antibiotics, anti-infectives, corticosteroids, oncology support, and critical care — and Midazolam Injection is a flagship product in our anesthesia and sedation portfolio.
Our export footprint spans 30+ countries across Africa, Southeast Asia, the Middle East, Latin America, and the CIS region. We have supported government tenders, hospital chains, and private distributors with consistent batch quality and complete regulatory documentation — including the controlled-substance paperwork that makes legitimate midazolam supply possible. Our long-term partners value the predictability of our delivery, the integrity of our documentation, and our willingness to engage on technical or regulatory questions in real time.
Our regulatory affairs team prepares CTD and ACTD dossiers, supports product registration filings, manages variations and renewals, and provides pharmacovigilance support. Technical leadership from Maulik Sudani and Jignasu Sudani — both with deep experience in sterile manufacturing and controlled-substance regulatory affairs — gives Farbe Firma the technical depth and commercial reliability that global Midazolam Injection buyers require.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions
What strengths of Midazolam Injection does Farbe Firma manufacture?
Farbe Firma manufactures Midazolam Injection in 1 mg/mL and 5 mg/mL strengths, supplied in 1 mL, 3 mL, and 5 mL clear glass ampoules and vials. Custom strengths, fill volumes, and pack configurations are available on request.
Is your Midazolam Injection WHO-GMP certified?
Yes. Our Midazolam Injection is manufactured under valid WHO-GMP certification, ISO 9001:2015 quality management, and Schedule M of the Indian Drugs and Cosmetics Act. Our Ankleshwar facility is open to audit by buyers, distributors, and regulatory authorities.
Can Farbe Firma support controlled-substance import-export documentation?
Yes. As an Indian manufacturer of a Schedule IV controlled substance, we hold the necessary Narcotics Control Bureau registrations and coordinate import permits, export authorizations, narcotic statements, and chain-of-custody records with both Indian authorities and the buyer's national narcotics control authority.
Do you provide CTD or ACTD dossiers for Midazolam Injection registration?
Yes. We provide complete CTD dossiers for ICH-aligned markets and ACTD dossiers for ASEAN-aligned markets, including stability data, validation reports, and Module 3 quality documentation needed to register the product in your jurisdiction.
What is the typical lead time for a Midazolam Injection order?
Lead time is typically 60–90 days from purchase order confirmation, including controlled-substance permit alignment, raw material procurement, manufacturing, QC release, and export documentation. Pre-aligned permits and stock buffer arrangements can shorten this significantly for long-term partners.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Farbe Firma Pvt Ltd | Website: www.farbefirma.org | Email: director@farbefirma.org | Gujarat, India
Request a Quote | View Products | FAQ | Blog
Comments